» Articles » PMID: 26240353

Flow Perfusion Effects on Three-dimensional Culture and Drug Sensitivity of Ewing Sarcoma

Overview
Specialty Science
Date 2015 Aug 5
PMID 26240353
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Three-dimensional tumor models accurately describe different aspects of the tumor microenvironment and are readily available for mechanistic studies of tumor biology and for drug screening. Nevertheless, these systems often overlook biomechanical stimulation, another fundamental driver of tumor progression. To address this issue, we cultured Ewing sarcoma (ES) cells on electrospun poly(ε-caprolactone) 3D scaffolds within a flow perfusion bioreactor. Flow-derived shear stress provided a physiologically relevant mechanical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elicited a superadditive release in the presence of exogenous IGF1. This finding is particularly relevant, given the central role of the IGF1/IGF-1 receptor (IGF-1R) pathway in ES tumorigenesis and as a promising clinical target. Additionally, flow perfusion enhanced in a rate-dependent manner the sensitivity of ES cells to IGF-1R inhibitor dalotuzumab (MK-0646) and showed shear stress-dependent resistance to the IGF-1R blockade. This study demonstrates shear stress-dependent ES cell sensitivity to dalotuzumab, highlighting the importance of biomechanical stimulation on ES-acquired drug resistance to IGF-1R inhibition. Furthermore, flow perfusion increased nutrient supply throughout the scaffold, enriching ES culture over static conditions. Our use of a tissue-engineered model, rather than human tumors or xenografts, enabled precise control of the forces experienced by ES cells, and therefore provided at least one explanation for the remarkable antineoplastic effects observed by some ES tumor patients from IGF-1R targeted therapies, in contrast to the lackluster effect observed in cells grown in conventional monolayer culture.

Citing Articles

Characterization of Vitronectin Effect in 3D Ewing Sarcoma Models: A Digital Microscopic Analysis of Two Cell Lines.

Lopez-Carrasco A, Parra-Haro K, Vieco-Marti I, Granados-Aparici S, Diaz-Martin J, Salguero-Aranda C Cancers (Basel). 2024; 16(19).

PMID: 39409975 PMC: 11476106. DOI: 10.3390/cancers16193347.


Continuous flow delivery system for the perfusion of scaffold-based 3D cultures.

Sitte Z, Karlsson E, Li H, Zhou H, Lockett M Lab Chip. 2024; 24(17):4105-4114.

PMID: 39099241 PMC: 11391725. DOI: 10.1039/d4lc00480a.


Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells.

Mierke C Cells. 2024; 13(1).

PMID: 38201302 PMC: 10777970. DOI: 10.3390/cells13010096.


Biomechanical Aspects in Bone Tumor Engineering.

Menshikh K, Banicevic I, Obradovic B, Rimondini L Tissue Eng Part B Rev. 2023; 30(2):217-229.

PMID: 37830183 PMC: 11001506. DOI: 10.1089/ten.TEB.2023.0106.


Beyond matrix stiffness: targeting force-induced cancer drug resistance.

Kalli M, Poskus M, Stylianopoulos T, Zervantonakis I Trends Cancer. 2023; 9(11):937-954.

PMID: 37558577 PMC: 10592424. DOI: 10.1016/j.trecan.2023.07.006.


References
1.
Cironi L, Riggi N, Provero P, Wolf N, Suva M, Suva D . IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One. 2008; 3(7):e2634. PMC: 2481291. DOI: 10.1371/journal.pone.0002634. View

2.
Tahimic C, Wang Y, Bikle D . Anabolic effects of IGF-1 signaling on the skeleton. Front Endocrinol (Lausanne). 2013; 4:6. PMC: 3563099. DOI: 10.3389/fendo.2013.00006. View

3.
Jaalouk D, Lammerding J . Mechanotransduction gone awry. Nat Rev Mol Cell Biol. 2009; 10(1):63-73. PMC: 2668954. DOI: 10.1038/nrm2597. View

4.
Subbiah V, Anderson P, Lazar A, Burdett E, Raymond K, Ludwig J . Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009; 10(1-2):126-40. DOI: 10.1007/s11864-009-0104-6. View

5.
Ludwig J, Lamhamedi-Cherradi S, Lee H, Naing A, Benjamin R . Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel). 2013; 3(3):3029-54. PMC: 3759185. DOI: 10.3390/cancers3033029. View